Industry Groups Petition To Block FDA Intended-Use Rule
Executive Summary
Trade groups say FDA’s redefinition of intended use is an overreach and would pose constitutional problems. The agency has yet to respond to a petition asking for the rule to be withdrawn.
You may also be interested in...
US FDA Clarifies ‘Intended Use’ Policy For Approved Products
‘Totality of evidence’ establishes that a manufacturer intends a drug to be used for unapproved conditions, agency says; PhRMA says final rule disregards multiple courts’ protection of free speech.
Vascular Solutions Case (Partially) Points Way Forward For Off-Label Marketing
Attorneys involved with a recent court ruling favoring Vascular Solutions believe the verdict might give manufacturers more latitude to engage in truthful, non-misleading, off-label speech. But caution is necessary.
US FDA, NIST Join Forces To Improve Manufacturing, Prevent Drug And Device Shortages
The focus on innovative manufacturing will also include a new clearinghouse to share info about advanced manufacturing technology within the US agency’s device center.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: